Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

Christoph Lange

13 ta ish

University of Lübeck

AkademScholarda batafsil koʻrsatkichlar

  1. Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

    Shama D. Ahuja, David Ashkin, Monika Avendano +70

    Sharh maqolaOchiq kirish20129 iqtibos
    ABI

  2. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

    Zhiyi Lan, Nafees Ahmad, Parvaneh Baghaei +35

    Sharh maqolaOchiq kirish20204 iqtibos
    ABI

  3. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

    Dennis Falzon, Neel R. Gandhi, Giovanni Battista Migliori +11

    Sharh maqolaOchiq kirish20124 iqtibos
    ABI

  4. Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis

    Mayara Lisboa Bastos, Hamidah Hussain, Karin Weyer +82

    Sharh maqolaOchiq kirish20144 iqtibos
    ABI

  5. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

    Nafees Ahmad, Shama D. Ahuja, Onno W. Akkerman +97

    Sharh maqolaOchiq kirish20184 iqtibos
    ABI

  6. Recent controversies about <scp>MDR</scp> and <scp>XDR‐TB</scp>: <scp>G</scp>lobal implementation of the <scp>WHO</scp> shorter <scp>MDR‐TB</scp> regimen and bedaquiline for all with <scp>MDR‐TB</scp>?

    Keertan Dheda, Helen Cox, Aliasgar Esmail +3

    Sharh maqolaOchiq kirish20172 iqtibos
    ABI

  7. Management of drug-resistant tuberculosis

    Christoph Lange, Keertan Dheda, Dumitru Chesov +3

    Sharh maqolaOchiq kirish20192 iqtibos
    ABI

  8. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

    Keertan Dheda, Tawanda Gumbo, Gary Maartens +39

    Sharh maqola20172 iqtibos
    ABI

  9. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe

    Christoph Lange, Raquel Duarte, M. Jachym +7

    Boshqa20162 iqtibos
    ABI

  10. Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon

    Sönke Andres, Matthias Merker, Jan Heyckendorf +8

    Boshqa20202 iqtibos
    ABI

  11. Characterization of patients with chronic pulmonary aspergillosis according to the new <scp>ESCMID</scp>/<scp>ERS</scp>/<scp>ECMM</scp> and <scp>IDSA</scp> guidelines

    Helmut J.F. Salzer, Jan Heyckendorf, Barbara Kalsdorf +2

    Maqola20162 iqtibos
    ABI

  12. Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

    S.K. Abidi, Jay Achar, M.M. Assao Neino +34

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyEuropean Respiratory Journal20191 iqtibos
    ABI

  13. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

    Anthony J. Garcia‐Prats, Maria Garcia‐Cremades, Vivian Cox +97

    Sharh maqolaOchiq kirishTuberculosis Research and EpidemiologyThe Lancet Child & Adolescent Health20250 iqtibos
    ABI